Description
Baloxavir, and its prodrug baloxavir marboxil, is a cap-dependent endonuclease inhibitor, leading to inhibition of RNA transcription and replication. Baloxavir shows potent activity against two influenza A strains with noted synergistic effects when used in combination with oseltamivir. It has also been investigated for its potential to treat COVID-19 but no proven benefit has been observed.